Biosimilar showdown: new drug tested against opdivo in melanoma
Disease control
Terminated
This study tested a new biosimilar drug (JPB898) against the approved immunotherapy Opdivo, both given with Yervoy, in people with advanced melanoma that cannot be removed by surgery. The goal was to see if the biosimilar works as well and is as safe as the original. The trial wa…
Phase: PHASE3 • Sponsor: Sandoz • Aim: Disease control
Last updated Apr 26, 2026 20:01 UTC